Under construction – not a live service

Skip to content

Frontlight Research

Trial site

NEXT Virginia

Fairfax, Virginia, United StatesNot linked to an institution yet

58running trials
14closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Recruiting
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
NCT07778498· Phase 1/2· Source
Recruiting
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
NCT07730021· Phase 1/2· Source
Recruiting
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959· Phase 1· Source
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506· Phase 1· Source
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322· Phase 1· Source
Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808· Phase 1/2· Source
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095· Phase 1· Source
Recruiting
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT07458347· Phase 1· Source
Recruiting
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855· Phase 1· Source
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572· Phase 1· Source
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· Phase 1/2· Source
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226· Phase 1/2· Source
Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995· Phase 1/2· Source
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338· Phase 1/2· Source
Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427· Phase 1· Source
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537· Phase 1· Source
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113· Phase 1· Source
Recruiting
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505· Phase 1· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047· Phase 1/2· Source
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150· Phase 1· Source
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168· Phase 1· Source
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· Source
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255· Phase 1/2· Source
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257· Phase 1/2· Source
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Source
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923· Phase 1· Source
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657· Phase 1· Source
Recruiting
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743· Phase 1· Source
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043· Phase 1/2· Source
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399· Phase 1· Source
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544· Phase 1/2· Source
Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT06799065· Phase 1/2· Source
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825· Phase 1· Source
Active, not recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132· Phase 1/2· Source
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076· Phase 1/2· Source
Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307· Phase 1· Source
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957· Phase 1· Source
Recruiting
Study of XB010 in Subjects With Solid Tumors
NCT06545331· Phase 1· Source
Recruiting
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252· Phase 1/2· Source
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· Phase 1/2· Source
Active, not recruiting
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738· Phase 1· Source
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925· Phase 1/2· Source
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069· Phase 1· Source
Active, not recruiting
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786· Phase 1· Source
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266· Phase 1/2· Source
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817· Phase 1/2· Source
Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686· Phase 1/2· Source
Recruiting
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706· Phase 1· Source
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741· Phase 1/2· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Terminated
A Study of PHN-010 in Patients With Advanced Solid Tumors
NCT06457997· Phase 1· Source
Completed
Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT06056791· Phase 1/2· Source
Terminated
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
NCT06052852· Phase 1· Source
Terminated
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
NCT05917470· Phase 1/2· Source
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751· Phase 1· Source
Terminated
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574· Phase 1· Source
Completed
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
NCT05538572· Phase 1· Source
Withdrawn
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
NCT05191004· Phase 1/2· Source
Withdrawn
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT05191017· Phase 1/2· Source
Terminated
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT05121103· Phase 1· Source
Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390· Phase 1· Source
Completed
A Study of PRT2527 in Participants With Advanced Solid Tumors
NCT05159518· Phase 1· Source
Completed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127· Phase 2/3· Source
Terminated
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
NCT04982224· Phase 1· Source

Site data: ClinicalTrials.govUpdated 7 Nov 2026

Report an error

Under construction, not live – NEXT Virginia: trial site – Frontlight Research